Self-Administered Drug Exclusion List (A53032) - R41 - Effective June 1, 2025

Date Posted: April 17, 2025

This billing and coding article has been revised and published for notice under contract numbers: 01112 (NCA), 01182 (SCA), 01212 (AS, GU, HI, NMI), and 01312 (NV).

Effective Date: June 1, 2025

Summary of Changes:

Added: CPT/HCPCS codes Q9999 Injection, Ustekinumab-aauz (Otulfi), biosimilar, 1 mg*; J3490, J3590, C9399 lebrikizumab-lbkz (Ebglyss); and J3490, J3590, C9399 ustekinumab-stba (SteQeyma)*

Visit the Self-Administered Drugs (SADs) webpage to view the Self-Administered Drug Exclusion List.

To view the complete listing of billing and coding articles and/or access the Active, Future, or Retired articles available in the CMS MCD, visit the Billing and Coding Articles webpage.

Last Updated Apr 17 , 2025